StudyofDWIpredictingtheefficacyofneoadjuvantchemotherapyindifferentmolecularsubtypesofbreastcancer
10.3969/j.issn.1002-1671.2019.05.015
- VernacularTitle:扩散加权成像预测不同分子亚型乳腺癌新辅助化疗疗效的研究
- Author:
Lian ZHAO
1
;
Hui GUO
;
Heji MA
Author Information
1. 锦州医科大学附属第一医院放射科
- Keywords:
diffusionweightedimaging;
breastcancer;
neoadjuvantchemotherapy;
molecularsubtypes;
efficacy
- From:
Journal of Practical Radiology
2019;35(5):747-751
- CountryChina
- Language:Chinese
-
Abstract:
Objective ToinvestigatethevalueoftheADCandtherelativeADC(rADC)ofDWIparameterstopredictthefinal pathologicalresponseintheearlystageofneoadjuvantchemotherapy(NAC)fordifferentmolecularsubtypesofbreastcancer.Methods TheresultsoftwoDWI(beforeNACandwithinoneweekaftersecondcycleofNAC)in116patientsenrolledinthestudywere retrospectivelyanalyzed.Theminimum ADCandrADCofthelesionsweremeasuredandrecorded,andtheirratesofchangeaftersecond cycle(ADC%、rADC%)werecalculated.Molecularsubtypeswererecordedaccordingtotheresultsofpreoperativeimmunohistochemistry, andpatientsweredividedintomajorhistologicalresponse(MHR)groupandnon-majorhistologicalresponse(NMHR)groupaccording topostoperativepathologicalgradingcriteriaofMiller&Payne.Results TherewasnocorrelationbetweentheADCbeforeNACand thefinalpathologicalresponseofeachsubtype.AftersecondcycleofNAC,exceptforLuminalA,ADCandADC%hadtheabilityof predictingfinalpathologicalresponsesfortheremainingsubtypes,especiallyinthehighestefficacyofADC%forthetriple-negative. BeforeNAC,rADChadpredictiveefficacyforLuminlBandHER2-enrichedsubtypes;aftersecondcycleofNAC,therADCdiffered onlybetweenthedifferentpathologicalresponsegroupsofHER2-enrichedandthetriple-negative,andthediagnosticefficacy was limited.TherADC%hadpredictiveefficacyonlyinthetriple-negativegroup.Conclusion ADChasnopredictiveefficacyforeach subtypebeforeNAC;WhiletherADCbeforeNAC,everyDWIparametersafter2ndcycleofNAC,andtheirchangeshavecertainvalues toevaluatethefinalpathologicalresponseofthecorrespondingpartialsubtypesofbreastcancer.
